Clinical Study 2 – BERT Study
Why is the BERT study conducted?
The BERT (Booster pertussis vaccine study) study investigates how cells in the blood respond to a recurrent vaccination against whooping cough. It determines whether this response depends on age, the number of vaccines that someone has received during his/her childhood and the type of vaccine that has been administered to someone in his/her youth. The study investigates the immune response in the blood of people of different ages. In the blood the amount of antibodies that someone produces for whooping cough is measured. Further, the reaction of the memory cells in the blood is investigated in different ways. These results can contribute to better vaccines in the future, thus optimizing the protection against whooping cough.
Whooping cough is an infection of the respiratory tract. This infection is caused by the bacterium Bordetella pertussis (B. pertussis) and is characterized mainly by a typical cough that often lasts for 3-4 months. The disease is also known as 'hundred-day cough'. Whooping cough is transmitted through droplet infection. In coughing patients, infectiousness lasts three weeks after the onset of the symptoms. Also someone without symptoms can infect others.
Where does the study take place?
The BERT study is conducted across three different clinical sites in Europe.
The Dutch National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM) is conducting the BERT study in cooperation with the Spaarne Gasthuis, a hospital in the Dutch city of Hoofddorp.
Further information on the Clinical Study can be found directly on the Website of the Rijksinstituut voor Volksgezondheid en Milieu, RIVM.
Visit: http://www.rivm.nl/Onderwerpen/V/Vaccinonderzoek/Kinkhoest/BERT_studie (all information is shown in Dutch)
Spaarnepoort 1, 2134 TM Hoofddorp, The Netherlands
University of Turku (UTU) in cooperation with the Turku University Hospital is recruiting heathy participants for the BERT study (Booster pertussis vaccine study). This vaccination study started 6.8.2018 in the Department of Pediatrics and Adolescent Medicine in Turku University Hospital.
Further information on the Clinical Study can be found directly on the Website of project in Turku.
Visit: http://hinku.utu.fi (all information is shown in Finnish)
Lasten ja nuorten klinikka
Kiinamyllynkatu 4-8, TYKS, 20520 Turku
The Oxford Vaccine Group (www.ovg.ox.ac.uk), which is part of the University of Oxford, is recruiting healthy adults and children to the BERT study in the UK.
Further information about participation in the study can be found on the following website: www.bertstudy.com
Oxford Vaccine Group
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)